Prostate

Papers
(The median citation count of Prostate is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
54
Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level36
Erratum to “Inhibition of Signaling Downstream of Beta‐2 Adrenoceptor by Propranolol in Prostate Cancer Cells”31
Impact of androgen receptor alterations on cell‐free DNA genomic profiling on survival outcomes in metastatic castration‐resistant prostate cancer27
VOC‐based detection of prostate cancer using an electronic nose and ion mobility spectrometry: A novel urine‐based approach26
Prognostic factors of overall and prostate‐specific antigen‐progression‐free survival in metastatic castration‐resistant prostate cancer patients treated with 177Lu‐PSMA‐617. A single‐cente26
Incidental Brain Metastases From Prostate Cancer Diagnosed With PSMA PET/CT and MRI: A Case Series and Literature Review25
Prognostic value of circulating tumor cells in oligorecurrent hormone‐sensitive prostate cancer patients undergoing stereotactic body radiation therapy24
Comprehensive Genomic Profiling Testing for Castration‐Resistant Prostate Cancer in Advanced Elderly Patients: A Single‐Center Retrospective Cohort Study23
The role of PSMA PET/CT to predict upgrading in patients undergoing radical prostatectomy for ISUP grade group 1 prostate cancer21
21
Investigation of pelvic floor influence on prostate displacement in image‐guided radiotherapy20
3βHSD activity saturates at physiological substrate concentrations in intact cells20
A west African ancestry‐associated SNP on 8q24 predicts a positive biopsy in African American men with suspected prostate cancer following PSA screening20
Association of plasma NRP2 and VEGF‐C levels with prostate cancer disease severity20
Histopathologic Features and Transcriptomic Signatures Do Not Solve the Issue of Magnetic Resonance Imaging‐Invisible Prostate Cancers: A Matched‐Pair Analysis19
19
Strong PD‐L1 expression in granulomatous prostatitis18
Issue Information18
Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter study18
The effect of tranexamic acid on perioperative blood loss in transurethral resection of the prostate: A double‐blind, randomized controlled trial17
Impact of Testosterone Recovery on Oncologic Outcomes in High‐Risk, Localized Prostate Cancer17
Analysis of three primary prostatic sarcoma cases and literature review17
A Comparative Study of the Global Burden of Prostate Cancer (1990–2021): Emphasis on the Disparities Between the United States and China17
Effect of BMI and hemoglobin A1c on survival of veterans with metastatic castration‐resistant prostate cancer treated with abiraterone or enzalutamide17
Metabolomic Insights Into Saliva as a Non‐Invasive Surrogate for Serum to Enable Community‐Based Biomarker Investigation17
Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate‐resistant prostate cancer post‐abiraterone and/or enzalutamide16
The 28th Annual Prostate Cancer Foundation Scientific Retreat report16
Intermediate‐term oncological and functional outcomes of salvage cryotherapy for the management of prostate cancer recurrence after primary brachytherapy versus primary cryotherapy: A propensity score15
Impact of definitive radiotherapy on metabolic response measured with 68Ga‐PSMA‐PET/CT in patients with intermediate‐risk prostate cancer15
Efficacy of Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperp15
Real‐world study: Impact of multidisciplinary management of apalutamide‐associated adverse events in prostate cancer15
Chromogenic detection of telomere lengths in situ aids the identification of precancerous lesions in the prostate15
EXPRESSION OF CONCERN: Functional p53 Determines Docetaxel Sensitivity in Prostate Cancer Cells15
Diagnostic and Prognostic Value of cfDNA Concentration and Fragmentation in Prostate Cancer15
Post Hoc Subgroup Analysis of Clinical Outcomes in Patients With High‐Risk Metastatic Hormone‐Naïve Prostate Cancer: Results From a 3‐Year Interim Analysis of the J‐ROCK Study15
A panel‐based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration‐resistant prostate cancer15
The Pubovesical Complex–Sparing Laparoscopic Radical Prostatectomy Improves Early Urinary Continence Without Compromising Oncologic Safety: A Prospective, Randomized, and Double‐Blinded Clinical Trial15
Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration‐resistant prostate cancer patients14
The association between beta‐blockers use and prostate cancer mortality: A mini systematic review and meta‐analysis14
Rezum water vapor therapy for patients with mild, moderate, or severe lower urinary tract symptoms: A retrospective study in a multiethnic population14
Image‐guided multiparametric magnetic resonance imaging‐transrectal ultrasound fusion biopsy augmented with a sextant versus an extended template random biopsy: Comparison of cancer detection rates, c14
14
Histologic inflammation and collagen content are not positively correlated in human BPH14
14
Factors Associated With Male Breast Cancer Incidence Among Prostate Cancer Survivors: Real World Evidence From Veterans Affairs National Prostate Cancer Data Core14
Issue Information14
Efficacy of Treatments for T3bN0M0 Prostate Cancer Patients: A Systematic Review and Meta‐Analysis14
Value of synthetic MRI quantitative parameters in preprocedural evaluation for TRUS/MRI fusion‐guided biopsy of the prostate14
Altered Glycosylation of PSA in Prostate Cancer Tissue14
13
Detection of intraductal carcinoma in prostate cancer patients with small tumor volume13
Characteristics of recurrent acute urinary retention in BPH patients in the United States: Retrospective analysis of US‐based insurance claims database13
Risk stratification for early biochemical recurrence of prostate cancer in the era of multiparametric magnetic resonance imagining‐targeted biopsy13
Cover Image: Volume 83 Issue 213
Zinc Ameliorates Inflammation and Sperm Parameters in Rats With Experimental Autoimmune Prostatitis13
Lack of repeatability of radiomic features derived from PET scans: Results from a 18 F‐DCFPyL test–retest cohort13
Emotion‐centered versus fact‐centered medical information to alleviate pain and anxiety in prostate biopsy: A randomized trial12
Probenecid and Eugenol Mitigate Testosterone Induced Benign Prostatic Hyperplasia by Targeting Uric Acid‐Induced Inflammation and Pro‐Survival Pathways12
12
Impact of Holmium Laser Enucleation of the Prostate on Active Surveillance for Prostate Cancer in Patients With Lower Urinary Tract Symptoms12
Three‐dimensional ultrastructural and anatomical analysis of prostatic neuroendocrine cells in mice12
Issue Information12
Lower urinary tract symptoms in elderly men: Considerations for prostate cancer testing12
Feasibility and preliminary clinical tolerability of low‐field MRI‐guided prostate biopsy12
Circulating microRNA profiling for prediction of oncological outcomes in prostate cancer patients following radical prostatectomy12
12
12
Proapoptotic effect of nonthermal pulsed ultrasound on prostate cancer cells in a nude mouse model12
Late Bowel Symptoms in Long‐Term Survivors of Prostate Cancer Following Radiotherapy12
Real‐world analysis of metastatic prostate cancer demonstrates increased frequency of PSA‐imaging discordance with visceral metastases and upfront ARAT/docetaxel therapy12
Distribution of neurovascular structures within the prostate gland and their relationship to complications after radical prostatectomy11
Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: A multicenter, open‐label, phase 2 trial11
Prostate Specific Antigen Density and Clinically‐Significant Prostate Cancer: The Influence of Prostatic Volume11
Better preservation of erectile function in localized prostate cancer patients with modern proton therapy: Is it cost‐effective?11
Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate‐specific antigen concentrations11
Evaluation of HNF1B, KLK3, ELAC2, TMPRSS2‐ERG, and CTNNB1 polymorphisms associated with prostate cancer in samples of patients from HUPE‐UERJ11
miRNAs Regulating GSTP1 as Potential Diagnostic Biomarkers in Prostate Cancer11
Berbamine targets cancer stem cells and reverses cabazitaxel resistance via inhibiting IGF2BP1 and p‐STAT3 in prostate cancer11
Long‐Term Follow‐Up of Neoadjuvant Enzalutamide Plus Androgen Deprivation Therapy in Localized Prostate Cancer: A Secondary Analysis of a Neoadjuvant Feasibility Trial11
Pathology of a Canine Model of Localized Prostate Carcinoma11
Factors impacting on sexual function among men on active surveillance for prostate cancer11
Prostate‐Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone‐Sensitive Prostate Cancer Treated With Apalutamide11
Understanding Enzalutamide‐Resistance Based on a Functional Single‐Cell Approach11
10
Issue Information10
Prostate Volume and PSA‐Density Estimation by Transabdominal Ultrasound: Prospective Evidence of Comparative Accuracy to MRI and Transrectal Ultrasound in Prostate Cancer Early Diagnostics10
Genetic Testing Among Black and White Patients With Advanced Prostate Cancer: A Retrospective Analysis of Testing Utilization and Referral Patterns10
A Phase II, Single Arm, Multicentre Trial of Triamcinolone With a GnRH Analog for Castrate‐Resistant Prostate Cancer (TRICREST)10
Issue Information10
Role of Volumetric Parameters Derived From Ga‐68 PSMA PET‐CT in Predicting Treatment Response10
10
Disease control outcomes of stereotactic body radiation therapy or moderate hypo‐fractionation for prostate cancer: Real‐world experience at two Canadian centers10
Multicenter External Validation and Optimization of a Proposed Nomogram for Prostate‐Specific Membrane Antigen PET/CT Accuracy in Biochemical Recurrence10
Tempol differential effect on prostate cancer inflammation: In vitro and in vivo evaluation10
ERG and PTEN Role on Active Surveillance for Low‐Risk Prostate Cancer in the Multiparametric MRI Era10
PIK3/Akt/mTOR pathway alterations in metastatic castration‐sensitive prostate cancer10
Nomograms for detecting lymph node metastasis detected with surgery—Can you name any birds other than crow?10
Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey−Holden prostate cancer academy meeting10
Issue Information10
The impact of genetic aberrations on response to radium‐223 treatment for castration‐resistant prostate cancer with bone metastases10
Predictive Value of PSA Bounce Phenomenon after Stereotactic Body Radiation Therapy in a Large Population of Prostate Cancer Patients Treated By 1.5 T MR Guided Adaptive Technique10
Quality of life outcomes for patients with metastatic castration‐resistant prostate cancer and pretreatment prognostic score9
Prognostic role of pan‐immune‐inflammation value in patients with metastatic castration‐resistant prostate cancer treated with androgen receptor‐signaling inhibitors9
hSSB1 (NABP2/OBFC2B) modulates the DNA damage and androgen‐induced transcriptional response in prostate cancer9
9
Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high‐risk localized prostate cancer9
Key learnings from concordant systematic biopsies in prostate‐specific membrane antigen positron emission tomography/computed tomography‐guided prostate biopsies: Enhancing targeting accuracy9
Issue Information9
Prostate and gut: Any relationship? A narrative review on the available evidence and putative mechanisms9
Coconut Oil Mitigates the Effects of Aging on the Mongolian Gerbil Prostate9
Genetics‐Driven, Intensity‐Modulated Adaptive Management of Patients With Metastatic Prostate Cancer9
Racial differences in circulating mitochondria‐derived peptides may contribute to prostate cancer health disparities9
Erratum to “Differential Impact of Paired Patient‐Derived BPH and Normal Adjacent Stromal Cells on Benign Prostatic Epithelial Cell Growth in 3D Culture”9
Issue Information9
Global Trends in Prostate Cancer Incidence Among Men Aged 55+ (1992–2021): An Age‐Period‐Cohort Analysis9
Evaluating the Heterogeneity of Advanced Prostate Cancer by 18F‐DCFPyL and 18F‐FDG PET/CT in a Prospective Cohort8
Evaluating Local Doses for Prostate Cancer Treatment Using Low‐Dose‐Rate Brachytherapy Considering Oncological Control and Toxicity8
Prostatic Surgery With Preservation of the Supramonticular Tissue Versus Standard Surgery for Benign Prostatic Hyperplasia: A Systematic Review8
Head‐to‐head comparison of GA‐68 PSMA PET/CT and multiparametric MRI findings with postoperative results in preoperative locoregional staging and localization of prostate cancer8
Patient‐reported functional outcomes and oncological control after primary focal cryotherapy for clinically significant prostate cancer: A Phase II mandatory biopsy‐monitored study8
Cumulative cancer locations on prostate biopsy and active surveillance outcomes in the MRI era8
8
8
Development and validation of a simple prostate cancer risk prediction model based on age, family history, and polygenic risk8
Comparison of Prognosis and Health‐Related Quality of Life Between Robot‐Assisted Radical Prostatectomy Versus High‐Dose‐Rate Brachytherapy Combined With External Beam Radiation Therapy and Hormone Th8
Polyphyllin I induces ferroptosis in castration‐resistant prostate cancer cells through the ERK/DNMT1/ACSL4 axis8
Safely omitting bone isotope scans in a cohort of grade group 2 prostate cancer8
Proteoglycans orchestrate remodeling of prostatic cytoarchitecture after androgenic blockade in old gerbils8
First, do no harm: The unclear benefit of lifelong castration for patients with metastatic prostate cancer8
Therapy decisions after diagnosis of prostate cancer in men with negative prostate MRI8
Clinical utility of the prognostic nutritional index in patients with metastatic hormone‐sensitive prostate cancer: A retrospective, multicenter, cohort study8
Diagnosis and management of neuroendocrine prostate cancer8
Prostate cancer focal therapy: surgeon experience influences oncological results8
Size and SUVmax define the contribution of nodal metastases to PSA in oligorecurrent prostate cancer7
Issue Information7
Issue Information7
Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real‐world setting of metastatic hormone‐sensitive prostate cancer patients7
Androgen receptor and MYC transcriptomes are equilibrated in multilayer regulatory circuitries in prostate cancer7
Issue Information7
7
Issue Information7
Melittin inhibits tumor cell migration and enhances cisplatin sensitivity by suppressing IL‐17 signaling pathway gene LCN2 in castration‐resistant prostate cancer7
Is prostatic adenocarcinoma with cribriform architecture more difficult to detect on prostate MRI?7
Survival Outcomes for Rural Patients With Advanced Prostate Cancer: A SEER Investigation7
Issue Information7
Serum levels of prostate specific antigen, free PSA, [−2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacoth7
7
Safety and Efficacy of Intra‐Prostatic Injection of Betamethasone for Refractory Chronic Nonbacterial Prostatitis: A Prospective Cohort Clinical Study7
The activated complement pathway in the fibrous process of benign prostatic hyperplasia7
Issue Information7
ATP8B1 : A prognostic prostate cancer biomarker identified via genetic analysis7
Issue Information7
Evidence and Rationale for Prostate Cancer Screening7
Mycobacterium Tuberculosis: The Hidden Bacteria in Chronic Prostatitis7
Clinical and histopathological parameters in transrectal ultrasound‐guided biopsies associated with tumor upgrading after radical prostatectomy: A comparative analysis of risk groups7
Efficacy and Feasibility of Cabazitaxel for Very Elderly Patients of ≥ 80 Years of Age With Metastatic Castration‐Resistant Prostate Cancer: A Real‐World Multi‐Intuitional Analysis7
Physician knowledge, practice patterns, and barriers encountered regarding guideline‐concordant use of bone modifying agents for prostate cancer7
The Role of Secondary Lesion Biopsy in Detecting Clinically Significant Prostate Cancer7
Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality7
Issue Information7
Issue Information7
A Feasibility Study of the Repurposing of Prazosin to Improve Treatment Outcomes in Men Receiving Radiotherapy for Prostate Cancer (MiniRaP‐00)7
Second Therapeutic Freeze After Salvage Cryoablation for Localized Radiorecurrent Prostate Cancer7
Bimodal imaging: Detection rate of clinically significant prostate cancer is higher in MRI lesions visible to transrectal ultrasound7
Evaluation of a photodynamic therapy agent using a canine prostate cancer model6
Chronic coexposure to arsenic and estrogen potentiates genotoxic estrogen metabolic pathway and hypermethylation of DNA glycosylase MBD4 in human prostate epithelial cells6
Overall and metastasis‐free survival of Afro‐Caribbean patients with biochemical recurrence after radical prostatectomy6
Risk factors for bladder neck contracture after transurethral resection of the prostate6
External validation of the Memorial Sloan Kettering Cancer Center preoperative nomogram predicting lymph node invasion in a cohort of high‐grade prostate cancer patients6
Radiographic paradoxical response in metastatic castrate‐resistant prostate cancer (mCRPC) managed with new generation anti‐androgens: a retrospective analysis6
Outcome of Subsequent Therapies After 177Lu‐Vipivotide Tetraxetan for Metastatic Castrate‐Resistant Prostate Cancer: A Tertiary Cancer Center Experience6
Prostate Cancer Cells With the AR‐Low and EMT‐High Phenotype Are Vulnerable to NAD+ Synthesis Inhibitors6
Prevalence of genotoxic bacteria in men undergoing biopsy for prostate cancer6
Comparative Evaluation of Detection Rates for Clinically Significant Prostate Cancer Using MRI‐Targeted Biopsy Alone Versus in Combination With Systematic Biopsies: Development of a Risk‐Stratificatio6
Discovering the Prostate: Notes on History and Historiography6
6
An update on the current status and future prospects of erectile dysfunction following radical prostatectomy6
Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate6
Utility of the PROSTest, a Novel Blood‐Based Molecular Assay, Versus PSA for Prostate Cancer Stratification and Detection of Disease6
The 30th Annual Prostate Cancer Foundation Scientific Retreat Report6
Cover Image: Volume 86 Issue 76
Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasis6
Adverse metabolic consequences of androgen deprivation therapy (ADT) on Asian patients with prostate cancer: Primary results from the real‐life experience of ADT in Asia (READT) study6
Real‐World Comparison of Triplet Versus Doublet Therapy in Japanese Patients With High‐Volume Metastatic Hormone‐Sensitive Prostate Cancer: A Propensity‐Weighted Analysis From the YUSHIMA Registry and6
Long‐Term Oncological Outcomes of Robot‐Assisted Radical Prostatectomy for Clinically Localized Grade Groups 4 and 5 Prostate Cancers Diagnosed on Prostate Biopsy6
Issue Information6
Clinicopathological Significance of Extranodal Adipose Tissue Invasion in Metastatic Lymph Nodes in Patients With Prostate Cancer6
Individualized Precision Prostate Biopsy Strategy for Patients With PI‐RADS Score 2: A Retrospective Multicenter Study6
USPSTF Recommendation Against PSA Screening vs. Stage and Cancer‐Specific Mortality in Localized Prostate Cancer6
Cover Image: Volume 83 Issue 35
Ten‐year functional and oncological outcomes of a prospective randomized controlled trial comparing laparoscopic versus robot‐assisted radical prostatectomy5
Targeting the fibroblast growth factor pathway in molecular subtypes of castration‐resistant prostate cancer5
Prognostic model for second progression‐free survival and overall survival in patients with high‐risk metastatic hormone‐sensitive prostate cancer treated with abiraterone acetate and androgen depriva5
Prostate Cancer Classification and Interpretation With Multiparametric Magnetic Resonance Imaging and Gleason Grade Score Using DarkNet53 Model5
18F‐sodium fluoride positron emission tomography quantitation of bone metastases in African American and non‐African American men with metastatic prostate cancer5
Significance of extraprostatic extension by Grade Groups 1–3 prostatic carcinoma on needle biopsy5
Long term update on toxicity and survival of a phase II trial of linac‐based stereotactic body radiation therapy for low‐intermediate risk prostate cancer5
Long‐term outcomes of radical prostatectomy versus low‐dose‐rate brachytherapy in patients with intermediate‐risk prostate cancer: Propensity score matched comparison5
Salvage stereotactic reirradiation for intraprostatic cancer recurrence: A large retrospective study5
Diagnostic Performance of the Novel Biomarker S2,3PSA Density for Prostate Biopsy Optimization in Prostate Imaging Reporting and Data System 3–5 Lesions5
Are higher pre‐diagnosis follicle stimulating hormone levels associated with long‐term prostate cancer risk?5
IU1 and enzalutamide combination yields synergistic effects on castration‐resistant prostate cancer5
Correction to “[Efficacy of Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign 5
Second malignancy probabilities in patients with prostate cancer treated with whole pelvis radiation therapy versus prostate only radiation therapy5
Prostate fibroblasts enhance androgen receptor splice variant 7 expression in prostate cancer cells5
Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration‐resistant prostate cancer5
Treatment Noncompletion and Shorter Radiation Regimens Among US Patients With Prostate Cancer: A Focus on Asian American and Pacific Islander Patients5
Variable effects of periprostatic adipose tissue on prostate cancer cells: Role of adipose tissue lipid composition and cancer cells related factors5
Conditional survival does not improve over time in metastatic castration‐resistant prostate cancer patients undergoing docetaxel5
CTPC, a combined transcriptome data set of human prostate cancer cell lines5
Robotic‐Assisted Radical Prostatectomy in the Elderly Patient—A Study of Functional, Surgical, and Oncological Outcomes in an Australian Cohort5
Issue Information5
Real‐world prevalence of adverse events with first‐line systemic therapies among patients with metastatic castration‐sensitive prostate cancer5
Evidence for a causal effect of major depressive disorder, anxiety on prostatitis risk: A univariate and multivariate Mendelian randomization study5
A CXCR4 inhibitor (balixafortide) enhances docetaxel‐mediated antitumor activity in a murine model of prostate cancer bone metastasis5
Use of Droplet Digital PCR for Consistent Detection of TMPRSS2:ERG Gene Fusion Transcripts Initiated In Vitro5
The Clinical Significance of Gallium‐68 PSMA‐11 PET‐Derived SUVmax in the Management of Metastatic Hormone‐Sensitive Prostate Cancer5
Microultrasound in the detection of the index lesion in prostate cancer5
Prostate cancer grade downgrading at time of prostatectomy provides risk‐stratification insight into future tumor behavior after prostatectomy5
Application of European‐specific polygenic risk scores for predicting prostate cancer risk in different ancestry populations5
Reply to Letter to the Editor on “Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration‐resistant prostate cancer patients”5
Other‐cause mortality in incidental prostate cancer5
Challenging the Evolving Nomenclature of Ultrasound‐Guided Transperineal Prostate Biopsy: A Call for Standardization5
Androgen Deprivation Therapy: Mitochondrial Dysfunction and Metabolic Impacts in Prostate Cancer5
Combining Prostate‐Specific Antigen Density With PI‐RADS to Improve the Detection of Clinically Significant Prostate Cancer at MRI/TRUS Fusion‐Targeted Re‐Biopsy5
Integration of Primary Care Into the Follow‐Up Protocol for Prostate Cancer Patients in Aragon, Spain. It Is Time to Follow Other Successful Models in the Region5
Confirmation of BIK and SAMHD1 as Prostate Cancer Susceptibility Genes5
Dose modification in enzalutamide and abiraterone plus prednisolone for castration‐resistant prostate cancer: A subanalysis from the ENABLE study for PCa4
Evaluating post radical prostatectomy mechanisms of early continence4
Efficiency and clinical outcomes of Moses technology for holmium laser enucleation of the prostate: An evidence‐based analysis4
Impact of COVID‐19 on the progression of benign prostatic hyperplasia and aggravation of related symptoms: A prospective study4
Clinical and molecular determinants of PSA response to bipolar androgen therapy in prostate cancer4
FOXA1 regulates ribosomal RNA transcription in prostate cancer4
LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA4
Translation and validation of a lifestyle questionnaire related to prostate cancer4
Decursin inhibits EGFR‐ERK1/2 signaling axis in advanced human prostate carcinoma cells4
The Mediterranean Diet and Benign Prostatic Hyperplasia: A Pathway to Improved Urinary Health4
A case of metastatic adenoid cystic (basal cell) carcinoma of the prostate: Systemic therapy for a rare disease4
Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy4
Real‐World Overall Survival Comparison of Enzalutamide and Abiraterone In First‐ and Second‐Line Setting of Metastatic Castration‐Resistant Prostate Cancer4
Effect of type of definitive treatment on race‐based differences in prostate cancer‐specific survival4
Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration‐Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate4
Incidence and risk factors of prostate cancer among the Northern and Eastern parts of the United Arab Emirates population4
Prostate Extracellular Vesicles and Prognostic Biomarkers of Clinically Significant Prostate Cancer: A Prospective Single‐Institution Pilot Study4
Issue Information4
Relationship Between Radiation Therapy and Fecal Incontinence in Patients Treated for Localized Prostate Cancer: Results of the French ICONES Study4
4
Evaluation of the optimal strategy in men with a single unilateral suspicious lesion on MRI undergoing transperineal MRI/ultrasound fusion prostate biopsy4
4
3.1048700809479